Rating Change
Barclays analysts reiterated a Overweight rating on Thermo Fisher Scientific Inc. (NYSE:TMO) on July 24, 2026.
reiterateNYSE:TMO
Barclays Reiterates Overweight Rating on Thermo Fisher Scientific Inc. (TMO)
Rating Change Barclays analysts reiterated a Overweight rating on Thermo Fisher Scientific Inc. (NYSE:TMO) on July 24, 2026. Market Context Thermo Fisher Scientific Inc.
Market Context
Thermo Fisher Scientific Inc. operates in the Healthcare sector. The stock currently trades at $568.26 with a market capitalization of $219.4B. The stock has declined 1.8% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Thermo Fisher Scientific Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Thermo Fisher Scientific Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 24, 2026 | Barclays | Overweight | N/A |
| Jul 24, 2026 | RBC Capital | Sector Perform | N/A |
| Jul 06, 2026 | Evercore ISI Group | Outperform | N/A |
| Jun 26, 2026 | Bernstein | Market Perform | N/A |
| Jun 11, 2026 | Piper Sandler | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View TMO Stock Page
Frequently Asked Questions
What does a Overweight rating mean for TMO?
A Overweight rating from Barclays reflects the analyst's outlook on Thermo Fisher Scientific Inc. (NYSE:TMO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TMO forecast page.
